gestational%20diabetes%20mellitus
GESTATIONAL DIABETES MELLITUS
Gestational diabetes mellitus (GDM) is any degree of glucose intolerance with onset or first recognition during pregnancy.
Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios.
Overt diabetes mellitus may be found in women presenting with risk factors for type 2 diabetes during the first prenatal visit (before 13 weeks of gestation).

Introduction

Gestational Diabetes Mellitus (GDM)
  • Any degree of glucose intolerance with onset or first recognition during pregnancy 
    • It is diabetes that is first diagnosed in the 2nd or 3rd trimester of pregnancy that has not been a pre-existing type 1 or 2 diabetes  
  • Hyperglycemia in pregnancy may be suggested by the presence of glycosuria, a fetus that is large for date, or polyhydramnios  
  • Prevalence of GDM appears to be high in South Asia and South East Asian women compared to African-American, Caucasian and Hispanic women; prevalence rates are 3-21.2% in women with GDM who were born in Asian countries  
    • Rates of fetal macrosomia are lower in South East Asian women than in American Caucasian women  
    • Asian women with GDM have a higher incidence of abnormal postpartum glucose tolerance tests and risk of developing type 2 DM in the future is higher than in Anglo-European women
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.

02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.